Generics access legislation
This article was originally published in The Tan Sheet
Executive Summary
The "Preserve Access to Affordable Generics Act" (S 316) has been approved by the Senate Judiciary Committee, according to a Feb. 15 announcement. The bill prohibits marketers of proprietary pharmaceuticals from paying generic drug companies to delay introduction of generic versions of drugs. Sen. Herb Kohl, D-Wis., et al. introduced the bill Jan. 17 to "support the purpose and intent of antitrust law by prohibiting anticompetitive agreements and collusion in the pharmaceutical industry," and to "clarify the law to prohibit payments from brand name generic drug manufacturers with the purpose to prevent or delay the entry of competition from generic drugs," according to the bill's text. The legislation also would require FTC to conduct a study on the prevalence in the pharmaceutical industry of anticompetitive agreements or other practices contrary to antitrust laws...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.